‘Pharma burnout’: Industry reputation slumps in first half of 2022, study finds
The biopharma industry reputation is sliding again — and alarmingly fast. The pharmaceuticals, biotechnology and life sciences category fell almost 3 points (2.9) between the first and second quarter of 2022, according to corporate reputation monitor RepTrak.
While a two- or three-point drop may not seem significant, RepTrak points out that its historical data “warns us that a 1-point drop often results in a 4-5% drop in support.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.